Group 1 - The company expects a net profit attributable to shareholders for the year 2025 to be between -130 million and -87 million yuan, with a net profit excluding non-recurring gains and losses projected to be between -186 million and -125 million yuan [1] - The performance of the company is significantly impacted by the cyclical nature and price fluctuations in the protective glove industry, as well as the appreciation of the RMB against the USD [1]

证券代码：300981 证券简称：中红医疗 公告编号：2026-010 中红普林医疗用品股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本期业绩预告情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为负值 （1）以区间数进行业绩预告 1、报告期内，防护手套类产品行业周期及价格波动，以及人民币对美元升 值等因素对公司业绩产生较大影响。 2、报告期内，公司结合行业发展、市场变化及经营情况，对部分出现减值 迹象的固定资产、存货计提减值准备合计约 0.27 亿元至 0.41 亿元，最终减值金 额以会计师事务所审计数据为准。 3、本报告期末，公司聘请的评估机构，对公司收购桂林恒保健康防护有限 公司（以下简称"恒保健康"）所形成的商誉进行了初步评估和测算。结合行业 发展、市场变化和实际经营情况等因素，判断恒保健康所形成的商誉出现减值迹 象。为更加客观、公正地反映公司的财务状况和资产价值，根据《企业会计准则 第 8 号-资产减值》等相关会计政策规定，按照谨慎性原则 ...

联系电话：0315-4155760 证券代码：300981 证券简称：中红医疗 公告编号：2026-009 中红普林医疗用品股份有限公司 关于公司董事会秘书取得任职培训证明并正式履职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）于 2025 年 11 月 17 日召开第四届董事会第十四次会议，审议通过了《关于聘任董事会秘书的议案》， 经公司薪酬考核与提名委员会审查通过后，同意聘任邓伟先生为公司第四届董事 会的董事会秘书，上述任期自本次董事会审议通过之日起至第四届董事会任期结 束之日止。鉴于聘任时，邓伟先生尚未取得深圳证券交易所认可的董事会秘书资 格证书，董事会指定其代行董事会秘书职责，待其取得相关资格证明后，正式履 行董事会秘书职责。具体内容详见 2025 年 11 月 17 日公司在巨潮资讯网 （www.cninfo.com.cn）披露的《关于董事会秘书辞职及聘任董事会秘书的公告》 （公告编号：2025-101）。 近日，邓伟先生已取得了深圳证券交易所颁发的上市公司董事会秘书培训证 明，根据公司第四届 ...

Investment Rating - The report maintains an "Outperform" rating for the medical and biotechnology industry [1]. Core Insights - The global demand for disposable gloves has recovered to pre-pandemic levels and is expected to grow steadily, with a projected compound annual growth rate (CAGR) of approximately 10% from 2022 to 2025, reaching a sales revenue of $13.6 billion by 2025 [3][11]. - The nitrile glove segment is anticipated to see significant growth, with the global medical nitrile glove market expected to reach $7.86 billion in 2024 and $16.31 billion by 2031, reflecting a CAGR of 11.2% from 2025 to 2031 [3][28]. - The industry is transitioning towards a balanced supply-demand scenario, with a gradual recovery in prices and profitability expected as high-cost capacities are phased out [4][47]. Summary by Sections Industry Overview - Disposable gloves are primarily used in medical settings, with nitrile gloves emerging as the preferred material due to their superior properties [9][12]. Market Cycle - The industry is expected to return to a phase of volume and price increases after experiencing supply-demand fluctuations, with a notable recovery in nitrile glove demand and pricing anticipated [22][46]. Investment Recommendations - The report suggests focusing on leading companies with advantages in capacity, cost control, and global expansion, such as Yingke Medical, Zhonghong Medical, and Blue Sail Medical [5][59]. Demand Side - The demand for disposable gloves is driven by increasing healthcare spending and heightened awareness of hygiene and protection across various sectors, particularly in developed markets [25][26]. Supply Side - The supply landscape is characterized by a concentration of production in Southeast Asia and China, with domestic leading manufacturers narrowing the capacity gap with Southeast Asian competitors [34][42]. Cost and Pricing Dynamics - The production costs of gloves are significantly influenced by raw material prices, particularly nitrile latex, which constitutes about 50% of production costs [50][54]. Price trends are expected to stabilize and potentially increase as demand recovers and high-cost production capacities exit the market [57][61].

Core Viewpoint - 中红医疗 plans to engage in low-risk financial investments and hedging activities in 2026 to enhance financial stability and mitigate risks associated with currency and commodity price fluctuations [1][2][3][5] Group 1: Financial Activities - 中红医疗 intends to use up to 2 billion RMB of idle funds to invest in low-risk financial products with a maximum investment period of 36 months [5] - The company plans to conduct foreign exchange derivative transactions with a maximum balance of 500 million USD to manage currency risk, using its own funds [2][3][4] - The company aims to engage in commodity futures hedging with a total transaction amount not exceeding 50 million RMB, also funded by its own resources [2][3] Group 2: Governance and Approval - The board of 中红医疗 approved several proposals on January 19, 2026, which will be submitted for shareholder approval at the first extraordinary general meeting on February 5, 2026 [1][5] - The proposals include the use of idle funds for low-risk investments, foreign exchange derivative transactions, and commodity futures hedging, with related party transactions requiring abstention from voting by related shareholders [1][2]

Trading Information - As of January 19, 2026, Zhonghong Medical (300981) closed at 13.39 yuan, up 0.75%, with a turnover rate of 0.89% and a trading volume of 34,900 shares, amounting to 46.4462 million yuan [1] - On January 19, 2026, the net outflow of main funds was 2.9472 million yuan, while retail investors saw a net inflow of 0.9156 million yuan [1] Company Announcements - Zhonghong Medical announced it will provide a guarantee of 50 million yuan for its wholly-owned subsidiary, Zhonghong International (Hong Kong) Trading Co., Ltd., in a financing contract with China Construction Bank [1] - The guarantee period is three years from the maturity of the main debt, and the subsidiary's latest asset-liability ratio is 94% [1] - The total guarantee amount for the company and its subsidiaries is 735 million yuan, accounting for 13.43% of the latest audited net assets, with no overdue guarantees [1] Board Meeting Resolutions - On January 19, 2026, Zhonghong Medical held its 16th meeting of the fourth board of directors, approving several proposals including the use of idle funds for low-risk financial products and foreign exchange derivatives trading [2] - The proposals will be submitted for approval at the first extraordinary shareholders' meeting of 2026, scheduled for February 5, 2026 [2] Financial Management Strategies - The company plans to invest up to 2 billion yuan of idle self-owned funds in low-risk financial products with a maximum investment period of 36 months [5] - The investment will focus on R1 and R2 rated financial products issued by commercial banks, trusts, and other financial institutions [5] - The company aims to conduct commodity futures hedging with a maximum trading margin of 5 million yuan and a total trading amount not exceeding 50 million yuan, using self-owned funds [3][4] Foreign Exchange Derivatives Trading - Zhonghong Medical intends to engage in foreign exchange derivatives trading to mitigate exchange rate risks, with a maximum balance of 500 million USD at any time [3][4] - The trading will include foreign exchange forwards, swaps, and options, with the funds sourced from self-owned capital [4]

Core Viewpoint - Zhonghong Medical (300981) has announced a temporary shareholders' meeting to discuss various financial strategies, including low-risk investment products and foreign exchange derivatives [1] Group 1: Stock Performance - As of January 19, 2026, Zhonghong Medical's stock closed at 13.39 yuan, up 0.75% from the previous trading day [1] - The stock opened at 13.2 yuan, reached a high of 13.46 yuan, and a low of 13.2 yuan, with a trading volume of 46.4462 million yuan and a turnover rate of 0.89% [1] Group 2: Shareholders' Meeting - The first temporary shareholders' meeting for 2026 is scheduled for February 5, 2026, at the Beijing Economic and Technological Development Zone [1] - The agenda includes proposals for using idle funds for low-risk financial products, engaging in foreign exchange derivatives trading, and conducting commodity futures hedging business, which involves related party transactions [1] - The record date for shareholders is January 29, 2026, and online voting will be conducted through the Shenzhen Stock Exchange system [1]

Group 1 - The company, Zhonghong Medical, announced that it will hold its first extraordinary general meeting of shareholders in 2026 on February 5 [2]

证券代码：300981 证券简称：中红医疗 公告编号：2026-008 中红普林医疗用品股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 三、被担保人基本情况 1. 公司名称：中红国际（香港）商贸有限公司 2. 法定代表人：施达 3. 注册资本：649,600 元 4. 成立日期：2011 年 10 月 25 日 5. 公司类型：其他有限责任公司 一、担保情况概述 中红普林医疗用品股份有限公司（以下简称"公司"）分别于 2025 年 12 月 8 日、2025 年 12 月 25 日召开第四届董事会第十五次会议、2025 年第四次临 时股东会，审议通过了《关于公司及子公司 2026 年度向银行申请综合授信额度 暨公司为子公司申请综合授信额度提供担保的议案》，同意公司为控股子公司 2026 年度向金融机构申请的授信额度提供担保，担保额度总计不超过 25 亿元， 其中，为资产负债率 70%（含）以上的控股子公司提供担保额度为不超过 15 亿 元。具体内容详见《关于公司及子公司 2026 年度向银行申请综合授信额度暨公 司 ...

Group 1 - The core point of the article is that Zhonghong Medical announced the approval of an investment plan for idle funds, allowing the company and its subsidiaries to invest up to 2 billion RMB in low-risk financial products for the year 2026 [1] Group 2 - The investment plan aims to ensure that the company meets its normal operational funding needs while utilizing idle funds effectively [1] - The approved financial products are characterized by high safety, good liquidity, stability, and controllable risks [1] - The investment will be valid for the year 2026 and will take effect after the first extraordinary shareholders' meeting of the company in 2026 [1]